A multicenter, open label, randomized, two treatment, parallel design, steady statestudy to compare the bioavailability of the Test product [Amphotericin B (Liposomefor injection) 50 mg/vial, Cipla Ltd., India] with Reference product [AmBisomeÂ®(Amphotericin B) Liposome for injection 50 mg/vial), Gilead life sciences, USA] inadult patients with visceral leishmaniasis.

Cipla Ltd India0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

阶段: 未知
状态: 招募中
发起方

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Ba/be

入排标准

入选标准

•1) Patients who have signed informed consent form before initiation of any study related procedure.
•2) Male and female patients who are >18 years of age at the time informed consent is obtained.
•3) Patients with visceral leishmaniasis.
•4) Able to comply with all the study procedures as per protocol.
•5) Patients with clinically insignificant laboratory values of hepatic, renal, hematopoietic and serum electrolytes at screening.
•6) The patient must be able to maintain the same regimen of the concomitant medications during the entire study.

排除标准

•1) History of hypersensitivity reactions to any components of conventional or liposomal Amphotericin B formulations.
•2) Patients who require dose adjustment during the study.
•3) Patients requiring any other concomitant drugs which have PK interaction with IMP.
•4) Historical or current evidence of a clinically significant disease including, but not limited to: cardiovascular (e.g.,congestive heart failure, known aortic aneurysm,clinically significant cardiac arrhythmia or coronary heart disease), hepatic, renal,hematological, neuropsychological, endocrine (e.g.,uncontrolled diabetes mellitus, uncontrolled thyroid disorder, Addisonâ??s disease, Cushingâ??s syndrome),gastrointestinal (e.g., poorly-controlled peptic ulcer, gastroesophageal reflux disease [GERD]), or pulmonary (e.g., chronic bronchitis, emphysema, bronchiectasis, cystic fibrosis, bronchopulmonary dysplasia, chronic obstructive pulmonary disease [COPD]) or obstructive sleep apnoea.
•5) Use of any investigational drug (approved or unapproved) within 30 days or 5 half-lives (whichever is longer) preceding the screening or planned participation in another investigational drug study at any time during this study.
•6) Donation / loss of blood (without replenishment) (1 unit or 350 mL) within 90
•days prior to receiving the first dose of study medicine.
•7) Patients with any abnormal/clinically significant lab value/s which may impair
•the safety during the study.
•8) Female patient who is pregnant or lactating. Pregnancy defined as state of a female after conception and until the termination of gestation (confirmed by positive serum/urine pregnancy test), lactating, or plans to become pregnant, or donate gametes (ova or sperm) for in vitro fertilization during the study period or for 30 days following the patientâ??s last study related visit.
•9) Women of childbearing potential unwilling to employ effective contraceptive methods or if they are of non-childbearing potential as defined below.
•ï? Methods of contraception include:
•i. Total abstinence (periodic abstinence and withdrawal are not acceptable contraceptive methods)
•ii. Surgical sterilization (tubal ligation, bilateral oophorectomy, or hysterectomy) at least 6 weeks before screening
•iii. Vasectomized male (done at least 6 months prior to screening) should be the sole partner for the female patient
•iv. Congenital sterility
•v. Use of oral, injected, or implanted hormonal methods of contraception or
•other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for e.g. vaginal ring, injectable progesterone or transdermal patches
•vi. Double barrier methods (condoms, cervical cap, diaphragm and vaginal contraceptive film with spermicide)
•vii. Intrauterine device (IUD)
•ï? Women of non-childbearing potential defined as:
•i. Surgical or congenital sterility
•ii. >1 year natural (spontaneous) amenorrhea

研究者

发起方

Cipla Ltd India

相似试验

招募中

不适用

To compare bioavailability of Paclitaxel protein-bound particles of Cipla Ltd.,India with ABRAXANEÂ® in Metastatic Breast cancer patients.

CTRI/2017/01/007746Cipla Ltd46

暂停

不适用

A study to compare Cipla product- Paclitaxel with Celgene Corporation product - ABRAXANEÂ® to establish that both are equally effective in treating metastatic breast cancer patients.

CTRI/2018/10/015972Cipla Ltd India

暂停

不适用

Bioequivalence study of Paliperidone Palmitate in schizophrenia patients

CTRI/2019/02/017754Amneal Pharmaceuticals Company GmbH

尚未招募

Unknown

This is a drug concentration assessment study of Azacitidine 300 mg tablets in patients with Blood Cancer (Acute Myeloid Leukemia).

CTRI/2024/03/064636PLIVA Croatia Ltd

已完成

不适用

To compare bioavailibility of Methotrexate Tablets 2.5 mg( Actavis LLC) with Methotrexate Tablets USP 2.5 mg (DAVA Pharmaceuticals, Inc.USA) in patients with mild to severe psoriasis or rheumatoid arthritis, who are already on establishedregimens of 2.5 mg every 12 hours under fasting condition.

CTRI/2015/05/005737Actavis LLC42